{"brief_title": "High-dose ICE With Amifostine", "brief_summary": "The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.", "condition": ["Bladder Cancer", "Brain and Central Nervous System Tumors", "Carcinoma of Unknown Primary", "Extragonadal Germ Cell Tumor", "Head and Neck Cancer", "Kidney Cancer", "Lung Cancer", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor", "Unspecified Adult Solid Tumor, Protocol Specific"], "intervention_type": ["Biological", "Drug", "Drug", "Drug", "Drug", "Procedure"], "intervention_name": ["filgrastim", "Amifostine", "Carboplatin", "Etoposide", "Ifosfamide", "peripheral blood stem cell transplantation"], "arm_group_label": ["High Dose ICF with Amifostine", "High Dose ICF with Amifostine", "High Dose ICF with Amifostine", "High Dose ICF with Amifostine", "High Dose ICF with Amifostine", "High Dose ICF with Amifostine"], "other_name": ["Ethyol\u00ae", "Paraplatin", "Toposar", "VePesid", "Etopophos", "Ifex"], "criteria": "Eligibility Criteria: - Histologically documented malignancy - Metastatic or locally unresectable malignancy - Patient may be responding to therapy - Responding Stage IIIC/IV or recurrent/refractory ovarian carcinoma (ineligible for other bone marrow or stem cell transplant protocols) - Relapsed germ cell carcinomas - Relapsed lymphomas (ineligible for other BMT or SCT protocols - SCLC in PR or CR - Sarcomas in or near complete remission after induction chemotherapy - Stage IIIB NSCLC responding to chemotherapy - Responsive bladder, head and neck carcinoma, or carcinoma of unknown primary - Other tumors without curative or first line therapy (not eligible for phase II or III studies) - Aged 18 to 55 Physiologic years -- Performance status: PS 0-1 - Prior Treatment - > 1 week since surgery or RT - > 3 weeks since prior CT - Informed Consent - Required initial laboratory data: - White Cell Count Life \u2265 3000/ul - Platelet Count \u2265 100,000/ul - Creatinine \u2264 1.5 x normal - Bilirubin \u2264 1.5 x normal - No current metastases - BM Asp & Bx - Brain CAT - Creatinine Clearance \u2265 60 cc/min - SGOT < 2.5 x normal - No other serious medical or psychiatric illness which would prevent informed consent or general anesthesia - Uncontrolled or severe cardiovascular disease including recent (< 6 months) myocardial infarction, or congestive heart failure - Active uncontrolled bacterial, viral, or fungal infection; or an active duodenal ulcer; until these conditions are corrected or controlled - Pregnancy - Unable to stop taking antihypertensive medication 24 hours prior to administration of Ethyol", "gender": "All", "minimum_age": "18 Years", "maximum_age": "55 Years", "healthy_volunteers": "No", "keyword": "stage IV adult soft tissue sarcoma", "mesh_term": ["Carcinoma", "Neoplasms", "Lung Neoplasms", "Sarcoma", "Head and Neck Neoplasms", "Urinary Bladder Neoplasms", "Neoplasms, Germ Cell and Embryonal", "Kidney Neoplasms", "Nervous System Neoplasms", "Central Nervous System Neoplasms", "Testicular Neoplasms", "Neoplasms, Unknown Primary", "Etoposide phosphate", "Isophosphamide mustard", "Carboplatin", "Etoposide", "Ifosfamide", "Amifostine", "Lenograstim"], "id": "NCT00003657"}